Serum cytokines are impacted by administration of tocilizumab, regardless of the occurrence of sCRS. (A) GMCSF; (B) TNFα; (C) INFγ; (D) IL-2; (E) IL-5; (F) IL-6; (G) IL-10; (H) IL-13; (I) granzyme B; (J) granzyme A; (K) MIP-1b; (L) sCD137; (M) sFas. Serum cytokines in the peripheral blood are noted by the maximum value following CAR T-cell infusion through day 28, grouped by patients who did and did not develop sCRS. *P ≤ .05, **P  ≤  .01, ***P  ≤  .001, ****P ≤ .0001.